SCHEMBL7490684

SCHEMBL7490684

COc1cc(/C=C\c2cc(OC)c(OC)c(OC)c2)ccc1N

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 12/20 0.78
TUBB4A P04350 8/20 0.78
TUBB P07437 8/20 0.78
TUBA3C P0DPH7 8/20 0.78
TUBA1B P68363 8/20 0.78
TUBA4A P68366 8/20 0.78
TUBB4B P68371 8/20 0.78
TUBB3 Q13509 8/20 0.78
TUBB2A Q13885 8/20 0.78
TUBB8 Q3ZCM7 8/20 0.78
TUBA3E Q6PEY2 8/20 0.78
TUBA1A Q71U36 8/20 0.78
TUBA1C Q9BQE3 8/20 0.78
TUBB6 Q9BUF5 8/20 0.78
TUBB2B Q9BVA1 8/20 0.78
APP P05067 3/20 0.72
CYP19A1 P11511 2/20 0.72
NQO2 P16083 1/20 0.72
SLC22A2 O15244 1/20 0.63
SLCO2B1 O94956 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7636432 1.00 TUBB1 (0.78) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5720643 0.91 APP (0.85) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL5720639 0.91 APP (0.85) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL291905 0.88 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29501731 0.88 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29611250 0.88 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL291904 0.88 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2144727 0.88 TUBB1 (1.00) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL27836944 0.87 TUBB1 (0.74) TUBB1TUBB4ATUBBTUBA3CTUBA1B
Hydrochloric Acid SCHEMBL6842165 0.86 TUBB1 (0.97) TUBB1TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9878977-B2 N-((3,4,5-trimethoxystyryl)aryl)cinnamamide compounds as potential anticancer agents and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-01-30 US disclosed
US-9878977-B2 N-((3,4,5-trimethoxystyryl)aryl)cinnamamide compounds as potential anticancer agents and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-01-30 US disclosed
US-20170240503-A1 N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2017-08-24 US disclosed
US-20170240503-A1 N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2017-08-24 US disclosed
US-20100069486-A1 ANTI-TUMOR COMPOSITION AJINOMOTO CO., INC. (JP) 2010-03-18 US disclosed
US-6350777-B2 METHOXY/ETHOXY SUBSTITUTED 3-AROYL-2-ARYLBENZO(B)THIOPHENES AND BENZO(B)THIOPHENE ANALOGUES; ANTITUMOR AGENTS; CYTOTOXICITY BAYLOR UNIVERSITY 2002-02-26 US disclosed
EP-0984954-A4 ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION UNIV BAYLOR (US) 2002-01-16 EP disclosed
US-20010034454-A1 Description anti-mitotic agents which inhibit tubulin polymerization BYLOR UNIVERSITY AND ARIZONA DESEASE CONTROL RESEARCH COMMISSION 2001-10-25 US disclosed
US-6162930-A Anti-mitotic agents which inhibit tubulin polymerization BAYLOR UNIVERSITY (US) 2000-12-19 US disclosed
EP-0984954-A1 ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION BAYLOR UNIVERSITY (US) 2000-03-15 EP disclosed
WO-1998039323-A1 ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION BAYLOR UNIVERSITY (US) 1998-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034454-A1 Description anti-mitotic agents which inhibit tubulin polymerization TUBB, TUBB1, TUBB3 TUBB1 2/4885TUBB4A 4/4885TUBB 1/4885
US-20100069486-A1 ANTI-TUMOR COMPOSITION TP53, VHL, MKI67 TUBB1 129/4885TUBB4A 194/4885TUBB 195/4885
US-20170240503-A1 N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP51A1, CBR3 TUBB1 286/4885TUBB4A 147/4885TUBB 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.